Lymphomas
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Na�ve Subjects with Follicular Lymphoma - PCYC-1141-CA
- Details
ClinicalTrials.gov ID:
NCT02947347
Diagnosis Type:
Non-Hodgkins
USOR Number:
- Address
,
P: